Legal & General Group
DYN icon

Legal & General Group’s Dyne Therapeutics DYN Stock Holding History

Legal & General Group’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.75M Sell
96,462
-21,660
-18% -$374K ﹤0.01% 1961
2025
Q4 		$2.31M Buy
118,122
+10,147
+9% +$192K ﹤0.01% 1912
2025
Q3 		$1.37M Buy
107,975
+29,442
+37% +$336K ﹤0.01% 2144
2025
Q2 		$748K Buy
78,533
+10,060
+15% +$111K ﹤0.01% 2321
2025
Q1 		$716K Buy
68,473
+8
+0% +$114 ﹤0.01% 2295
2024
Q4 		$1.61M Sell
68,465
-37,982
-36% -$1.12M ﹤0.01% 2069
2024
Q3 		$3.82M Buy
106,447
+46,113
+76% +$1.84M ﹤0.01% 1698
2024
Q2 		$2.13M Buy
60,334
+16,233
+37% +$472K ﹤0.01% 1922
2024
Q1 		$1.25M Buy
44,101
+19,827
+82% +$448K ﹤0.01% 2118
2023
Q4 		$323K Buy
24,274
+182
+0.8% +$1.78K ﹤0.01% 2605
2023
Q3 		$216K Sell
24,092
-408
-2% -$4.39K ﹤0.01% 2706
2023
Q2 		$276K Buy
24,500
+13,796
+129% +$163K ﹤0.01% 2663
2023
Q1 		$123K Buy
10,704
+282
+3% +$3.66K ﹤0.01% 2736
2022
Q4 		$121K Hold
10,422
– – ﹤0.01% 2776
2022
Q3 		$133K Sell
10,422
-2,335
-18% -$26.8K ﹤0.01% 2742
2022
Q2 		$88K Buy
12,757
+4,779
+60% +$32.9K ﹤0.01% 2887
2022
Q1 		$77K Hold
7,978
– – ﹤0.01% 2925
2021
Q4 		$95K Hold
7,978
– – ﹤0.01% 2920
2021
Q3 		$129K Buy
7,978
+4,577
+135% +$81.1K ﹤0.01% 2797
2021
Q2 		$71K Buy
3,401
+1,685
+98% +$31.7K ﹤0.01% 2840
2021
Q1 		$27K Buy
1,716
+239
+16% +$4.63K ﹤0.01% 3022
2020
Q4 		$31K Buy
1,477
+982
+198% +$19.4K ﹤0.01% 2940
2020
Q3 		$10K Buy
+495
New +$10.9K ﹤0.01% 3223

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Legal & General Group's DYN Position: Q1 2026 in Review

Legal & General Group reduced its Dyne Therapeutics (DYN) stake by 18% in Q1 2026, selling an estimated $374K and leaving 96,462 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Legal & General Group first reported a position in DYN in Q3 2020 and has held it in 23 quarters since. The position peaked at $3.82M in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Legal & General Group held 96,462 shares of Dyne Therapeutics worth $1.75M as of Q1 2026.
  • Legal & General Group sold 21,660 Dyne Therapeutics shares in Q1 2026, an estimated $374K.
  • Dyne Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1961 holding.
  • Legal & General Group first reported a position in Dyne Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Legal & General Group's Dyne Therapeutics position peaked at $3.82M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.